SARS-CoV-2 Compound Screening in Respiratory Organoids
SARS-CoV-2 is a serious threat to our global community. PBA has temporarily put its internal programs on hold and is now helping research teams around the world develop vaccines and therapeutics combating this virus.
PBA provides primary respiratory epithelial organoids for in vitro SARS-CoV-2 studies.
Readouts include viral gene copy number, viral titers, gene expression changes, inflammatory markers, and others, in 96-well plates.
To discuss your project, email us at firstname.lastname@example.org
Precision Medicine - Made Possible
Developing drugs for indications with high unmet need through patient-derived disease models and artificial intelligence
Precision medicine–tailoring drug treatment
to specific patient populations–holds enormous potential for the future of healthcare. Here at PBA, we conduct phenotypic drug discovery and development using patient-derived disease models and AI to advance treatments for targeted patient populations.
We believe that precision medicine can address the complexities of disease and biological interactions on the whole-genome level.
PBA is developing drugs for multiple indications, including cystic fibrosis, COPD, celiac disease and chronic rhinosinusitis.